DNA for expression under control of a cell cycle-dependent promoter

US6358732B1 · kind B1 · utility

Assignee

• Aventis Pharma Deutschland GmbH · DE

Inventors

• Hans-Harald Sedlacek · Marburg, DE
• Rolf Muller · Marburg, DE

Key dates

• Filing date: Apr 25, 1997
• Grant date: Mar 19, 2002
• Expiry date: Apr 25, 2017

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2830/85
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A DNA sequence is disclosed for the genetic therapy of diseases of the central nervous system. The essential components for the DNA sequence are the activator sequence, the promoter module, and the active substance coding gene. The activator sequence is specifically activated in activated endothelial or glial cells. Activation is cell cycle-regulated by the promoter module. The active substance represents an inhibitor of the nerve growth factor, a dopanine metabolism enzyme, and/or a nerve cell protection factor. The disclosed DNA sequence is inserted into a viral or non-viral vector, supplemented with a ligand with affinity for the target cells.